pegmolesatide
Peptideexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started May 31, 2025 (NCT06946394)
Timeline
No events for the selected filters.
Indications
Mechanism of action
- Erythropoietin receptorAGONIST
EPOR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07136792 | N/A | Aug 31, 2025 | Shantou University |
| NCT07045155 | Phase 4 | Aug 1, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd., People's Liberation Army of China |
| NCT06946394 | Phase 4 | May 31, 2025 | Dalian Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 2 | 0 | 1 | 2025 |
| Dalian Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2025 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1